| NCT06185543 | A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. | RECRUITING | PHASE2 | 2023-11-19 | 2025-11 | 2025-11 |
| NCT05436678 | A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject | COMPLETED | PHASE1 | 2022-07-26 | 2022-10-20 | 2022-08-19 |
| NCT05357950 | A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS | COMPLETED | PHASE2 | 2022-05-31 | 2024-11-04 | 2023-11-02 |
| NCT05232461 | A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects | COMPLETED | PHASE1 | 2022-04-08 | 2022-08-30 | 2022-04-21 |
| NCT04090684 | Ciprofloxacin/Celecoxib Combination in Patients With ALS | COMPLETED | PHASE1 | 2019-12-09 | 2022-01-20 | 2021-09-27 |
| NCT04165850 | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS | COMPLETED | PHASE2 | 2019-11-25 | 2021-01-19 | 2021-01-19 |